Medicare Part D coverage · methsuximide · RxCUI 207088
methsuximide 300 MG Oral Capsule [Celontin]
Per the CMS 2026 Part D formulary file, methsuximide 300 MG Oral Capsule [Celontin] is covered by 163 Medicare Part D plans (3.2% of enrollable products), averaging Tier 3.2, with prior authorization required on 0% of covering formularies.
- 3.2%
- Plan coverage
- 163
- Plans covering
- T3.2
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for methsuximide 300 MG Oral Capsule [Celontin]
Per the CMS 2026 Part D formulary file, methsuximide 300 MG Oral Capsule [Celontin] (RxNorm concept RXCUI 207088, generic name methsuximide) appears on 10 distinct formulary files spanning 163 Medicare Part D plan offerings - 3.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.2.
Real-world access to methsuximide 300 MG Oral Capsule [Celontin] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 217 Part D beneficiaries filled methsuximide 300 MG Oral Capsule [Celontin] in 2023, with total plan-and-beneficiary spending of $695,875 and an average per-beneficiary annual cost of $3,206.80. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry methsuximide 300 MG Oral Capsule [Celontin] today.
Coverage Details
- Formularies covering
- 10
- Plans covering
- 163
- Coverage rate
- 3.2%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 217
- Total spending
- $695,875
- Avg per beneficiary
- $3,206.80
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering methsuximide 300 MG Oral Capsule [Celontin]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is methsuximide 300 MG Oral Capsule [Celontin] covered by Medicare Part D?
Yes, methsuximide 300 MG Oral Capsule [Celontin] is covered by 163 Medicare Part D plans (3.2% of all Part D formularies).
What tier is methsuximide 300 MG Oral Capsule [Celontin] on Medicare Part D plans?
methsuximide 300 MG Oral Capsule [Celontin] averages Tier 3.2 across Part D plans, ranging from Tier 1 to Tier 4.
Does methsuximide 300 MG Oral Capsule [Celontin] require prior authorization?
0% of Part D formularies require prior authorization for methsuximide 300 MG Oral Capsule [Celontin]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on methsuximide 300 MG Oral Capsule [Celontin]?
In 2023, total Medicare Part D spending on methsuximide 300 MG Oral Capsule [Celontin] was $695,875, covering 217 beneficiaries. The average spend per beneficiary was $3,206.80.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 0.5 ML diazepam 5 MG/ML Rectal Gel T3.2
- phenytoin sodium 30 MG Extended Release Oral Capsule [Dilantin] T3.2
- alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix 4.25/5] T3.2
- alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution [Clinimix 5/20] T3.2
- citric acid 68.6 MG/ML / magnesium oxide 20 MG/ML / picosulfate sodium 0.0571 MG/ML Oral Solution [Clenpiq] T3.2
- fluorometholone acetate 1 MG/ML Ophthalmic Suspension [Flarex] T3.2